These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

643 related items for PubMed ID: 28853040

  • 1. State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease.
    Puri L, Nottage KA, Hankins JS, Anghelescu DL.
    Paediatr Drugs; 2018 Feb; 20(1):29-42. PubMed ID: 28853040
    [Abstract] [Full Text] [Related]

  • 2. Fentanyl Buccal Tablet: A New Breakthrough Pain Medication in Early Management of Severe Vaso-Occlusive Crisis in Sickle Cell Disease.
    De Franceschi L, Mura P, Schweiger V, Vencato E, Quaglia FM, Delmonte L, Evangelista M, Polati E, Olivieri O, Finco G.
    Pain Pract; 2016 Jul; 16(6):680-7. PubMed ID: 26009799
    [Abstract] [Full Text] [Related]

  • 3. Mouse Models of Pain in Sickle Cell Disease.
    Sagi V, Song-Naba WL, Benson BA, Joshi SS, Gupta K.
    Curr Protoc Neurosci; 2018 Oct; 85(1):e54. PubMed ID: 30265442
    [Abstract] [Full Text] [Related]

  • 4. Comparison of Parenteral Opioid Dosing in Adult Sickle Cell Disease Patients With Vaso-occlusive Crisis.
    Shah SP, Twilla JD, Kemp L, Phelps GL, Reaves A.
    J Pain Palliat Care Pharmacother; 2018 Dec; 32(4):201-207. PubMed ID: 30896312
    [Abstract] [Full Text] [Related]

  • 5. Pain Control for Sickle Cell Crisis, a Novel Approach? A Retrospective Study.
    Rollé A, Vidal E, Laguette P, Garnier Y, Delta D, Martino F, Portecop P, Etienne-Julan M, Piednoir P, De Jong A, Romana M, Bernit E.
    Medicina (Kaunas); 2023 Dec 18; 59(12):. PubMed ID: 38138299
    [Abstract] [Full Text] [Related]

  • 6. Targeting novel mechanisms of pain in sickle cell disease.
    Tran H, Gupta M, Gupta K.
    Blood; 2017 Nov 30; 130(22):2377-2385. PubMed ID: 29187376
    [Abstract] [Full Text] [Related]

  • 7. A multimodal pain protocol for treatment of vaso-occlusive crisis in patients with sickle cell disease: Implementation and evaluation.
    Admiraal M, van Daalen J, Ritt MWJ, Dekker J, van Tuijn CFJ, Nur E, Hollmann MW, Hermanns H, Hermanides J, Biemond BJ.
    Eur J Haematol; 2023 Sep 30; 111(3):382-390. PubMed ID: 37277324
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pain in sickle cell disease: current and potential translational therapies.
    Sagi V, Mittal A, Tran H, Gupta K.
    Transl Res; 2021 Aug 30; 234():141-158. PubMed ID: 33711512
    [Abstract] [Full Text] [Related]

  • 10. Low-dose ketamine as a potential adjuvant therapy for painful vaso-occlusive crises in sickle cell disease.
    Neri CM, Pestieau SR, Darbari DS.
    Paediatr Anaesth; 2013 Aug 30; 23(8):684-9. PubMed ID: 23565738
    [Abstract] [Full Text] [Related]

  • 11. Pain management in children and adolescents with sickle cell disease.
    Jerrell JM, Tripathi A, Stallworth JR.
    Am J Hematol; 2011 Jan 30; 86(1):82-4. PubMed ID: 20949441
    [Abstract] [Full Text] [Related]

  • 12. A Randomized Trial of Yoga for Children Hospitalized With Sickle Cell Vaso-Occlusive Crisis.
    Moody K, Abrahams B, Baker R, Santizo R, Manwani D, Carullo V, Eugenio D, Carroll A.
    J Pain Symptom Manage; 2017 Jun 30; 53(6):1026-1034. PubMed ID: 28192225
    [Abstract] [Full Text] [Related]

  • 13. Use of a clinical pathway to improve the acute management of vaso-occlusive crisis pain in pediatric sickle cell disease.
    Ender KL, Krajewski JA, Babineau J, Tresgallo M, Schechter W, Saroyan JM, Kharbanda A.
    Pediatr Blood Cancer; 2014 Apr 30; 61(4):693-6. PubMed ID: 24249617
    [Abstract] [Full Text] [Related]

  • 14. New and emerging treatments for vaso-occlusive pain in sickle cell disease.
    Dampier C.
    Expert Rev Hematol; 2019 Oct 30; 12(10):857-872. PubMed ID: 31364883
    [Abstract] [Full Text] [Related]

  • 15. Patient characteristics affect the response to ketamine and opioids during the treatment of vaso-occlusive episode-related pain in sickle cell disease.
    Nobrega R, Sheehy KA, Lippold C, Rice AL, Finkel JC, Quezado ZMN.
    Pediatr Res; 2018 Feb 30; 83(2):445-454. PubMed ID: 28902183
    [Abstract] [Full Text] [Related]

  • 16. Is morphine exposure associated with acute chest syndrome in children with vaso-occlusive crisis of sickle cell disease? A 6-year case-crossover study.
    Finkelstein Y, Schechter T, Garcia-Bournissen F, Kirby M, Nurmohamed L, Juurlink DN, Blanchette V, Koren G.
    Clin Ther; 2007 Dec 30; 29(12):2738-43. PubMed ID: 18201591
    [Abstract] [Full Text] [Related]

  • 17. Opioid selection during sickle cell pain crisis and its impact on the development of acute chest syndrome.
    Buchanan ID, Woodward M, Reed GW.
    Pediatr Blood Cancer; 2005 Oct 15; 45(5):716-24. PubMed ID: 15926170
    [Abstract] [Full Text] [Related]

  • 18. An innovative short-stay health care model for treatment of uncomplicated vaso-occlusive crisis in adult sickle cell disease patients in Canada to reduce emergency department utilization.
    Binding A, Ward R, Phua C, Naessens V, O'Brien T, Bhatia S, Baranek H, Marani H, Mukerji G.
    CJEM; 2019 Jan 15; 21(1):55-62. PubMed ID: 29039292
    [Abstract] [Full Text] [Related]

  • 19. Management of Chronic Pain in Adults Living With Sickle Cell Disease in the Era of the Opioid Epidemic: A Qualitative Study.
    Sinha CB, Bakshi N, Ross D, Krishnamurti L.
    JAMA Netw Open; 2019 May 03; 2(5):e194410. PubMed ID: 31125105
    [Abstract] [Full Text] [Related]

  • 20. Dexmedetomidine as an Adjuvant to Analgesic Strategy During Vaso-Occlusive Episodes in Adolescents with Sickle-Cell Disease.
    Sheehy KA, Finkel JC, Darbari DS, Guerrera MF, Quezado ZM.
    Pain Pract; 2015 Nov 03; 15(8):E90-7. PubMed ID: 26205912
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.